Reckitt Benckiser Group (LON:RKT) Shares Up 1.9% – What’s Next?

Shares of Reckitt Benckiser Group plc (LON:RKT) shot up 1.9% during mid-day trading on Monday . The stock traded as high as GBX 5,172 ($64.39) and last traded at GBX 5,166 ($64.32). 90,327,430 shares traded hands during trading, an increase of 757% from the average session volume of 10,544,096 shares. The stock had previously closed at GBX 5,072 ($63.15).

Analyst Ratings Changes

Separately, Berenberg Bank decreased their target price on shares of Reckitt Benckiser Group from GBX 5,200 ($64.74) to GBX 5,177 ($64.45) and set a “hold” rating for the company in a research report on Wednesday, October 23rd.

Reckitt Benckiser Group Price Performance

The company has a current ratio of 0.69, a quick ratio of 0.46 and a debt-to-equity ratio of 112.52. The firm has a market cap of £36.24 billion, a price-to-earnings ratio of 2,416.59, a price-to-earnings-growth ratio of 1.10 and a beta of 0.09. The company’s 50-day moving average is GBX 4,883.66 and its 200-day moving average is GBX 4,651.11.

Insider Buying and Selling at Reckitt Benckiser Group

In other news, insider Shannon Eisenhardt sold 1,368 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of GBX 4,723 ($58.80), for a total value of £64,610.64 ($80,441.53). Corporate insiders own 0.05% of the company’s stock.

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.